Response to a Letter Received Entitled: "'Brief Report: Canadian Cancer Trials Group IND.227': Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma"

J Thorac Oncol. 2023 Jun;18(6):e68-e69. doi: 10.1016/j.jtho.2023.03.003.

¹ Clinical Trials Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, Italy.
² Cross Cancer Instiute, Alberta Health Services/University of Alberta, Edmonton. Alberta, Canada.
³ Princess Margaret Cancer Centre, University Health Network/University of Toronto, Toronto, Ontario, Canada.
⁴ Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada. Electronic address: [email protected].

No abstract available

Publication types